loading
전일 마감가:
$53.84
열려 있는:
$53.35
하루 거래량:
400.26K
Relative Volume:
1.12
시가총액:
$2.27B
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-12.32
EPS:
-4.54
순현금흐름:
$-146.15M
1주 성능:
-1.24%
1개월 성능:
-5.75%
6개월 성능:
+9.41%
1년 성능:
+84.19%
1일 변동 폭
Value
$53.06
$57.33
1주일 범위
Value
$52.63
$57.33
52주 변동 폭
Value
$27.31
$73.00

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
명칭
Keros Therapeutics Inc
Name
전화
617-314-6297
Name
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
직원
160
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
KROS's Discussions on Twitter

KROS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
KROS 55.92 2.27B 0 -168.05M -146.15M -4.54
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-02-21 개시 William Blair Outperform
2023-12-08 개시 Wells Fargo Overweight
2023-07-31 개시 Wedbush Outperform
2023-07-26 개시 BofA Securities Buy
2023-02-14 개시 Cowen Outperform
2022-10-18 개시 Truist Buy
2022-07-26 개시 BTIG Research Buy
2020-12-08 재확인 H.C. Wainwright Buy
2020-05-04 개시 H.C. Wainwright Buy
2020-05-04 개시 Jefferies Buy
2020-05-04 개시 Piper Sandler Overweight
2020-05-04 개시 SVB Leerink Outperform
모두보기

Keros Therapeutics Inc 주식(KROS)의 최신 뉴스

pulisher
10:01 AM

Cantor Fitzgerald Reaffirms Overweight Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat

10:01 AM
pulisher
05:10 AM

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

05:10 AM
pulisher
Nov 22, 2024

Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

Nov 22, 2024
pulisher
Nov 21, 2024

Keros Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 21, 2024
pulisher
Nov 16, 2024

Long Term Trading Analysis for (KROS) - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 11, 2024

What is Leerink Partnrs’ Estimate for KROS FY2024 Earnings? - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

Equities Analysts Offer Predictions for KROS FY2024 Earnings - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

What is HC Wainwright's Estimate for KROS FY2024 Earnings? - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Wedbush Decreases Earnings Estimates for Keros Therapeutics - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Issues Pessimistic Forecast for KROS Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Has Negative Outlook of KROS FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Wedbush Equities Analysts Cut Earnings Estimates for KROS - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 Earnings Estimate for KROS Issued By HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023) - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Brokers Offer Predictions for KROS Q3 Earnings - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

Q3 Earnings Estimate for KROS Issued By Wedbush - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Interesting KROS Put And Call Options For April 2025 - Nasdaq

Nov 07, 2024
pulisher
Nov 07, 2024

HC Wainwright Reaffirms Buy Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Brokers Set Expectations for KROS Q4 Earnings - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

KROSKeros Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Keros Therapeutics to Present at Guggenheim Conference - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Brokers Issue Forecasts for KROS Q4 Earnings - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Wedbush Upgrades Keros Therapeutics (NASDAQ:KROS) to Strong-Buy - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Jefferies starts Keros Therapeutics with buy, $107 target By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

(KROS) Proactive Strategies - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 05, 2024

Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Nov 05, 2024
pulisher
Nov 03, 2024

Emerald Advisers LLC Acquires Shares of 155,545 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11 - Defense World

Nov 01, 2024
pulisher
Oct 30, 2024

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Analysts Offer Predictions for KROS FY2024 Earnings - Defense World

Oct 29, 2024
pulisher
Oct 28, 2024

Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Cantor Fitzgerald Weighs in on KROS FY2024 Earnings - Defense World

Oct 28, 2024
pulisher
Oct 28, 2024

Brokers Set Expectations for KROS FY2024 Earnings - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

(KROS) Trading Signals - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 25, 2024

Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat

Oct 24, 2024
pulisher
Oct 16, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics appoints new Chief Medical Officer - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics, Inc. Appoints Yung H. Chyung as Chief Medical Officer, Effective as of November 1, 2024 - Marketscreener.com

Oct 16, 2024
pulisher
Oct 16, 2024

Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Declines By 13.7% - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Objective long/short (KROS) Report - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 09, 2024

Renaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Oct 09, 2024
pulisher
Oct 09, 2024

Renaissance Technologies LLC Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Oct 09, 2024

Keros Therapeutics Inc (KROS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Keros Therapeutics Inc 주식 (KROS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
ORBIMED ADVISORS LLC
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):